CA2591929A1 - Polypeptides secretes et transmembranaires et acides nucleiques codant lesdits polypeptides - Google Patents
Polypeptides secretes et transmembranaires et acides nucleiques codant lesdits polypeptides Download PDFInfo
- Publication number
- CA2591929A1 CA2591929A1 CA002591929A CA2591929A CA2591929A1 CA 2591929 A1 CA2591929 A1 CA 2591929A1 CA 002591929 A CA002591929 A CA 002591929A CA 2591929 A CA2591929 A CA 2591929A CA 2591929 A1 CA2591929 A1 CA 2591929A1
- Authority
- CA
- Canada
- Prior art keywords
- acid sequence
- nucleic acid
- sequence identity
- alternatively
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 81
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 64
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 64
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 64
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 15
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 15
- 238000000034 method Methods 0.000 claims abstract description 14
- 239000013598 vector Substances 0.000 claims abstract description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 66
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 63
- 239000002773 nucleotide Substances 0.000 claims description 52
- 125000003729 nucleotide group Chemical group 0.000 claims description 52
- 210000004027 cell Anatomy 0.000 claims description 25
- 108091026890 Coding region Proteins 0.000 claims description 12
- 108020004414 DNA Proteins 0.000 claims description 10
- 230000008569 process Effects 0.000 claims description 7
- 239000000523 sample Substances 0.000 claims description 6
- 238000004113 cell culture Methods 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 4
- 108060003951 Immunoglobulin Proteins 0.000 claims description 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 claims description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 2
- 102000018358 immunoglobulin Human genes 0.000 claims description 2
- 239000002751 oligonucleotide probe Substances 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims 3
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 239000013068 control sample Substances 0.000 claims 2
- 210000005253 yeast cell Anatomy 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 13
- 102000005962 receptors Human genes 0.000 description 11
- 108020003175 receptors Proteins 0.000 description 11
- 239000012634 fragment Substances 0.000 description 10
- 108010076504 Protein Sorting Signals Proteins 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 102000053602 DNA Human genes 0.000 description 6
- 239000000556 agonist Substances 0.000 description 6
- 239000005557 antagonist Substances 0.000 description 6
- 230000004069 differentiation Effects 0.000 description 6
- 230000000295 complement effect Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 3
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 102000003839 Human Proteins Human genes 0.000 description 2
- 108090000144 Human Proteins Proteins 0.000 description 2
- 108090000189 Neuropeptides Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000003145 cytotoxic factor Substances 0.000 description 2
- 239000000032 diagnostic agent Substances 0.000 description 2
- 229940039227 diagnostic agent Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 239000003226 mitogen Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- -1 survival factors Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 108091005703 transmembrane proteins Proteins 0.000 description 2
- 102000035160 transmembrane proteins Human genes 0.000 description 2
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 108091008794 FGF receptors Proteins 0.000 description 1
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000007339 Nerve Growth Factor Receptors Human genes 0.000 description 1
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 101800001357 Potential peptide Proteins 0.000 description 1
- 102400000745 Potential peptide Human genes 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 108091005682 Receptor kinases Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 102000040739 Secretory proteins Human genes 0.000 description 1
- 108091058545 Secretory proteins Proteins 0.000 description 1
- 108090000184 Selectins Proteins 0.000 description 1
- 102000003800 Selectins Human genes 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 239000002787 antisense oligonuctleotide Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 108010037896 heparin-binding hemagglutinin Proteins 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
Applications Claiming Priority (61)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2000/015264 WO2000073452A2 (fr) | 1999-06-02 | 2000-06-02 | Compositions et methodes de traitement de maladies liees a l'immunite |
| WOPCT/USOO/15264 | 2000-06-02 | ||
| US20983200P | 2000-06-05 | 2000-06-05 | |
| US60/209,832 | 2000-06-05 | ||
| US21290100P | 2000-06-20 | 2000-06-20 | |
| US60/212,901 | 2000-06-20 | ||
| US21380700P | 2000-06-22 | 2000-06-22 | |
| US60/213,807 | 2000-06-22 | ||
| US21955600P | 2000-07-20 | 2000-07-20 | |
| US60/219,556 | 2000-07-20 | ||
| US22066600P | 2000-07-25 | 2000-07-25 | |
| US22060700P | 2000-07-25 | 2000-07-25 | |
| US22066400P | 2000-07-25 | 2000-07-25 | |
| US22062400P | 2000-07-25 | 2000-07-25 | |
| US22058500P | 2000-07-25 | 2000-07-25 | |
| US22063800P | 2000-07-25 | 2000-07-25 | |
| US22060500P | 2000-07-25 | 2000-07-25 | |
| US60/220,585 | 2000-07-25 | ||
| US60/220,664 | 2000-07-25 | ||
| US60/220,638 | 2000-07-25 | ||
| US60/220,624 | 2000-07-25 | ||
| US60/220,607 | 2000-07-25 | ||
| US60/220,605 | 2000-07-25 | ||
| US60/220,666 | 2000-07-25 | ||
| US22089300P | 2000-07-26 | 2000-07-26 | |
| US60/220,893 | 2000-07-26 | ||
| WOPCT/US00/20710 | 2000-07-28 | ||
| PCT/US2000/020710 WO2001009327A2 (fr) | 1999-07-28 | 2000-07-28 | Procede de prevention de la deterioration ou de la mort des cellules de la retine et de traitement des troubles oculaires |
| US22242500P | 2000-08-01 | 2000-08-01 | |
| US60/222,425 | 2000-08-01 | ||
| US22713300P | 2000-08-22 | 2000-08-22 | |
| US60/227,133 | 2000-08-22 | ||
| WOPCT/US00/23522 | 2000-08-23 | ||
| PCT/US2000/023522 WO2001016319A2 (fr) | 1999-08-31 | 2000-08-23 | Compositions et procedes pour le traitement de maladies d'ordre immunologique |
| PCT/US2000/023328 WO2001016318A2 (fr) | 1999-09-01 | 2000-08-24 | Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci |
| WOPCT/US00/23328 | 2000-08-24 | ||
| US23288700P | 2000-09-15 | 2000-09-15 | |
| US60/000,000 | 2000-09-15 | ||
| WOPCT/US0030873 | 2000-11-10 | ||
| PCT/US2000/030873 WO2001040465A2 (fr) | 1999-11-30 | 2000-11-10 | Compositions et procedes de traitement de maladies d'ordre immunologique |
| US25364600P | 2000-11-28 | 2000-11-28 | |
| US60/253,646 | 2000-11-28 | ||
| WOPCT/US00/32678 | 2000-12-01 | ||
| PCT/US2000/032678 WO2001040466A2 (fr) | 1999-12-01 | 2000-12-01 | Polypeptides secretes et transmembranaires et acides nucleiques codant ces polypeptides |
| WOPCT/US00/34956 | 2000-12-20 | ||
| US09/747,259 US6569645B2 (en) | 1999-05-14 | 2000-12-20 | IL-17 homologous polypeptides and therapeutic uses thereof |
| PCT/US2000/034956 WO2001046420A2 (fr) | 1999-12-23 | 2000-12-20 | Polypeptides homologues de l'il-17 et leurs utilisations therapeutiques |
| US09/747,259 | 2000-12-20 | ||
| PCT/US2001/006520 WO2001068848A2 (fr) | 2000-03-01 | 2001-02-28 | Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides |
| WOPCT/US01/06520 | 2001-02-28 | ||
| US0166666 | 2001-03-01 | ||
| USPCT/US01/066666 | 2001-03-01 | ||
| US09/816,744 | 2001-03-22 | ||
| US09/816,744 US6579520B2 (en) | 1998-05-15 | 2001-03-22 | IL-17 related mammalian cytokine polypeptides (IL-17E) |
| US09/854,280 US7115398B2 (en) | 1998-05-15 | 2001-05-10 | IL-17 homologous polypeptides and therapeutic uses thereof |
| US09/854,208 US7217412B2 (en) | 1998-05-15 | 2001-05-10 | IL-17C related mammalian cytokine polypeptides |
| US09/854,208 | 2001-05-10 | ||
| US09/854,280 | 2001-05-10 | ||
| WOPCT/US01/17092 | 2001-05-25 | ||
| PCT/US2001/017092 WO2001092331A2 (fr) | 2000-05-30 | 2001-05-25 | Compositions et methodes de traitement de maladies d'origine immune |
| CA002410162A CA2410162A1 (fr) | 2000-06-02 | 2001-06-01 | Polypeptide pro 4332 marqueur de tumeurs du poumon, du colon, du rectum et du sein et acide nucleique codant pour ce polypeptide |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002410162A Division CA2410162A1 (fr) | 2000-06-02 | 2001-06-01 | Polypeptide pro 4332 marqueur de tumeurs du poumon, du colon, du rectum et du sein et acide nucleique codant pour ce polypeptide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2591929A1 true CA2591929A1 (fr) | 2001-12-13 |
Family
ID=38653227
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002591929A Abandoned CA2591929A1 (fr) | 2000-06-02 | 2001-06-01 | Polypeptides secretes et transmembranaires et acides nucleiques codant lesdits polypeptides |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2591929A1 (fr) |
-
2001
- 2001-06-01 CA CA002591929A patent/CA2591929A1/fr not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Williams et al. | Stromal interaction molecule 1 (STIM1), a transmembrane protein with growth suppressor activity, contains an extracellular SAM domain modified by N-linked glycosylation | |
| EP1003863B1 (fr) | Recepteur 11 de cytokines de mammiferes | |
| AU743490B2 (en) | NTN-2 member of TNF ligand family | |
| Kroczek et al. | Defective Expression of CD40 Ligand on T Cells Causes “X‐Linked Immunodeficiency with Hyper‐IgM (HIGM1)” | |
| CA1328419C (fr) | Recepteurs pour la detection efficace de ligands et de leurs antagonistes ou agonistes | |
| CN112375784B (zh) | 制备重组新型冠状病毒Spike蛋白的方法 | |
| JP4777570B2 (ja) | テザード・リガンド及び使用方法 | |
| CA2433514A1 (fr) | Recepteurs du gout t1r et genes les codant | |
| WO1998055621A1 (fr) | Membre ntn-2 de la famille des ligands du facteur de necrose tumorale (tnf) | |
| JP2005046146A5 (fr) | ||
| AU2019216086C1 (en) | PD-1 variant having improved binding to PD-L1 | |
| CA2146328A1 (fr) | C-c ckr-1, recepteur c-c chemokine | |
| EP1019502A2 (fr) | Nouveau recepteur orphelin | |
| US20020160451A1 (en) | Novel orphan receptors | |
| CA2340686A1 (fr) | Nouvelles molecules de la famille des proteines associees au mediateur d'entree du virus de l'herpes et leurs applications | |
| CA2591929A1 (fr) | Polypeptides secretes et transmembranaires et acides nucleiques codant lesdits polypeptides | |
| EP0585801B1 (fr) | Protéine du type cadhérinique apparentée aux os et procédé de production | |
| WO1998001541A1 (fr) | Proteine kinase associee a traf-2 et dosages | |
| AU748167B2 (en) | Novel nucleic acid and polypeptide | |
| KR19990063834A (ko) | 단형 케모킨 베타-8 | |
| WO2000066736B1 (fr) | Homologue du facteur de croissance zvegf4 | |
| RU2230751C2 (ru) | Пептид mpi без сигнальной последовательности, днк, его кодирующая, вектор, способ определения способности к секретированию тестируемого пептида, способ выделения кднк | |
| CA2323572A1 (fr) | Proteine de vertebre patched-2 | |
| CN117304300A (zh) | 人il-31ra的突变体及其应用 | |
| JPH11318452A (ja) | ヒト脳からの新規ｇ蛋白質―結合レセプタ― |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |